Stocks › RARE
Ultragenyx Pharmaceutical Inc.
RARE·Nasdaq·
United States·USD
United States·USD$14.89
+0.43 (+2.97%)
Close · Oct 7, 2026 · Close Prices from Tiingo.com
RARE
Ultragenyx Pharmaceutical Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
RARES&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of RARE by members of U.S. Congress · 4 on record · 2 in the last 12 months
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
 Gilbert Ray Cisneros, Jr.House · D · CA |
RAREUltragenyx Pharmaceutical Inc. · Stock |
Purchase $1,001 - $15,000 |
Apr 7, 2026 | Mar 3, 2026 | Filing ↗ |
| Gilbert Ray Cisneros, Jr.House · D · CA |
RAREUltragenyx Pharmaceutical Inc. · Stock |
Purchase $1,001 - $15,000 |
Mar 9, 2026 | Feb 18, 2026 | Filing ↗ |
| Gilbert Ray Cisneros, Jr.House · D · CA |
RAREUltragenyx Pharmaceutical Inc. · Stock |
Purchase $1,001 - $15,000 |
Sep 12, 2025 | Aug 8, 2025 | Filing ↗ |
| Gilbert Ray Cisneros, Jr.House · D · CA |
RAREUltragenyx Pharmaceutical Inc. · Stock |
Purchase $1,001 - $15,000 |
Aug 14, 2025 | Jul 15, 2025 | Filing ↗ |
Whale Activity
Position changes in RARE reported for 2026-06-30 by 14 tracked institutional filers
- Increased5
- New0
- Held0
- Decreased3
- Closed1
- No prior filing5
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 10.7M | $355.7M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6.8M | $226.7M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.3M | $143.5M | increased |
| TWO SIGMA INVESTMENTS, LP | 3.6M | $120.9M | increased |
| SANDS CAPITAL MANAGEMENT, LLC | 3.2M | $105.5M | — |
| D. E. Shaw & Co., Inc. | 1.7M | $57.8M | increased |
| MILLENNIUM MANAGEMENT LLC | 760.8K | $25.4M | decreased |
| Palo Alto Investors LP | 596.5K | $19.9M | — |
| RENAISSANCE TECHNOLOGIES LLC | 413.7K | $13.8M | decreased |
| GordonMD Global Investments LP | 289.1K | $9.7M | — |
| CITADEL ADVISORS LLC | 210.5K | $7.0M | decreased |
| Knott David M Jr | 38.1K | $1.3M | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by RARE insiders, by quarter · Form 4
Recent Insider Transactions
1,138 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Huizenga Theodore AlanSVP, Chief Accounting Officer | Sale | −1,283 | $13.57 | $17K | Sep 15, 2026 | Form 4 ↗ |
| Huizenga Theodore AlanSVP, Chief Accounting Officer | Sale | −161 | $13.99 | $2K | Sep 3, 2026 | Form 4 ↗ |
| Parschauer Karah HerdmanEVP and Chief Legal Officer | Sale | −1,900 | $24.92 | $47K | Aug 3, 2026 | Form 4 ↗ |
| Horn HowardChief Financial Officer | Sale | −4,696 | $24.92 | $117K | Aug 3, 2026 | Form 4 ↗ |
| Horn HowardChief Financial Officer | Sale | −4,698 | $33.13 | $156K | Jul 1, 2026 | Form 4 ↗ |
| Sanders Corazon (Corsee) D.Director | Sale | −2,000 | $25.05 | $50K | Jun 15, 2026 | Form 4 ↗ |
| Parschauer Karah HerdmanEVP and Chief Legal Officer | Sale | −1,899 | $24.62 | $47K | Jun 15, 2026 | Form 4 ↗ |
| Horn HowardChief Financial Officer | Sale | −4,653 | $23.77 | $111K | Jun 1, 2026 | Form 4 ↗ |
| SULIMAN SHEHNAAZDirector | Sale | −5,740 | $25.12 | $144K | May 18, 2026 | Form 4 ↗ |
| Ray AmritDirector | Grant / award | +7,751 | $0.00 | $0 | May 14, 2026 | Form 4 ↗ |
| Sanders Corazon (Corsee) D.Director | Grant / award | +7,751 | $0.00 | $0 | May 14, 2026 | Form 4 ↗ |
| SULIMAN SHEHNAAZDirector | Grant / award | +7,751 | $0.00 | $0 | May 14, 2026 | Form 4 ↗ |
| Fust Matthew KDirector | Grant / award | +7,751 | $0.00 | $0 | May 14, 2026 | Form 4 ↗ |
| NARACHI MICHAELDirector | Grant / award | +7,751 | $0.00 | $0 | May 14, 2026 | Form 4 ↗ |
| WELCH DANIEL GDirector | Grant / award | +7,751 | $0.00 | $0 | May 14, 2026 | Form 4 ↗ |
| Dunsire DeborahDirector | Grant / award | +7,751 | $0.00 | $0 | May 14, 2026 | Form 4 ↗ |
| Crombez EricEVP and Chief Medical Officer | Sale | −344 | $24.96 | $9K | May 5, 2026 | Form 4 ↗ |
| Horn HowardChief Financial Officer | Sale | −4,683 | $24.90 | $117K | May 1, 2026 | Form 4 ↗ |
| Huizenga Theodore AlanSVP, Chief Accounting Officer | Grant / award | +20.2K | $0.00 | $0 | Apr 22, 2026 | Form 4 ↗ |
| KAKKIS EMIL DPresident & CEO · Director | Grant / award | +76.7K | $0.00 | $0 | Apr 16, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding RARE · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 3.7M | $122.4M | 1.14% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 3.0M | $99.7M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 2.5M | $83.5M | 0.10% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 2.1M | $71.6M | 0.04% | Jun 30, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 1.2M | $41.4M | 0.09% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.1M | $37.7M | 0.04% | Jun 30, 2026 |
| VANGUARD STRATEGIC EQUITY FUND VANGUARD HORIZON FUNDS | 1.1M | $35.8M | 0.29% | Jun 30, 2026 |
| AQR Long-Short Equity Fund AQR Funds | 914.7K | $30.5M | 0.39% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 1.1M | $26.3M | 0.08% | Jul 31, 2026 |
| iShares Biotechnology ETF iShares Trust | 635.3K | $21.2M | 0.23% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list RARE's shares (CUSIP 90400D108), each fund at its latest report since Mar 8, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Roderick WongSCHEDULE 13G · passive (13G) · 7.8M shares7.9%
Aug 14, 2026 · ↗ - RTW Investments, LPSCHEDULE 13G · passive (13G) · 7.8M shares7.9%
Aug 14, 2026 · ↗ - AQR Capital Management Holdings, LLCSCHEDULE 13G · passive (13G) · 6.6M shares6.7%
Aug 13, 2026 · ↗ - AQR Capital Management, LLCSCHEDULE 13G · passive (13G) · 6.6M shares6.7%
Aug 13, 2026 · ↗ - STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 6.2M shares6.3%
Aug 7, 2026 · ↗ - Vanguard Portfolio ManagementSCHEDULE 13G/A · passive (13G) · 6.9M shares7.0%
Jul 31, 2026 · ↗ - Vanguard Capital ManagementSCHEDULE 13G · passive (13G) · 5.1M shares5.1%
Jul 31, 2026 · ↗ - BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 8.1M shares8.3%
Jul 30, 2026 · ↗ - STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 5.0M shares5.1%
May 12, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming Ultragenyx Pharmaceutical Inc. as client
This section is temporarily unavailable, reload in a minute.
Government Contracts
Federal awards to Ultragenyx Pharmaceutical Inc. · USAspending
This section is temporarily unavailable, reload in a minute.
U.S. Patents
Recent USPTO applications naming Ultragenyx Pharmaceutical Inc.
This section is temporarily unavailable, reload in a minute.
Annual Financials
From RARE's 10-K filings · XBRL
No annual XBRL figures on record for RARE. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
This section is temporarily unavailable, reload in a minute.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 1.01Material agreementOct 7, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsSep 17, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsSep 2, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsAug 19, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsAug 11, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 4, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteMay 18, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 5, 2026
EDGAR ↗
About Ultragenyx Pharmaceutical Inc.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersNOVATO, CA
IncorporatedDE
SEC CIK0001515673 ↗